Stock IONS IONIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
41.99 USD +0.96% Intraday chart for Ionis Pharmaceuticals, Inc. +2.24% -17.00%
04-11 North American Morning Briefing : Stock Futures -2- DJ
04-10 Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome
Sector Update: Health Care Stocks Gain Premarket Wednesday
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224
Ionis Pharmaceuticals, Inc. Announces Executive Changes
Travere drug for rare kidney condition recommended for EU approval
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell
Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2023
Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS
GSK : une procédure accélérée dans l'hépatite aux USA
Ionis Pharmaceuticals Says US FDA Grants Fast Track Designation to Eplontersen
Ionis Pharmaceuticals Insider Sold Shares Worth $1,160,303, According to a Recent SEC Filing
Ionis Pharmaceuticals Insider Sold Shares Worth $333,788, According to a Recent SEC Filing
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study
Ionis Pharma's genetic disease drug succeeds in late-stage study
Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IONS Stock
  4. News Ionis Pharmaceuticals, Inc.
  5. Other languages